期刊
PEDIATRIC BLOOD & CANCER
卷 68, 期 5, 页码 -出版社
WILEY
DOI: 10.1002/pbc.28922
关键词
acute lymphoblastic leukaemia; blinatumomab; paediatric; refractory; relapse
资金
- Cancer Australia [PdCCRS1128727]
- National Health and Medical Research Council [APP1142627]
- Children's Leukaemia and Cancer Research Foundation
- Kids' Cancer Project
This study reports on the Australian experience of using blinatumomab for the treatment of 24 children with relapsed/refractory B-cell acute lymphoblastic leukemia, showing a MRD response rate of 58% and 2-year survival rates. However, not all patients responded to blinatumomab, and factors such as blast genotype may affect prognosis.
We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据